U.S., Feb. 14 -- ClinicalTrials.gov registry received information related to the study (NCT06825208) titled 'Etoposide Plus Benmelstobart Followed by Maintenance Therapy of Benmelstobart Plus Anlotinib in First-line Treatment of Elderly Patients with Extensive Stage Small Cell Lung Cancer: a Single-arm, Prospective Trial' on Feb. 09.
Brief Summary: This is a prospective, single-arm clinical study to evaluate the efficacy and safety of etoposide in combination with bemosubezumab and sequential Benmelstobart in combination with Anlotinib as first-line treatment for elderly patients with extensive small-cell lung cancer.
Participants who met the inclusion criteria were selected to enter the study and received etoposide combined with Benmelst...